propan-2-yl (2S)-2-[[methyl(phenoxy)phosphoryl]amino]propanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: propan-2-yl (2S)-2-[[methyl(phenoxy)phosphoryl]amino]propanoate
• 化学式: C₁₃H₂₀NO₄P
• 分子量: 285.28
• InChiKey: BMWLMKWXWGIGHC-JEOXALJRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING HCV
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20140309164A1

  公开（公告）日：2014-10-16

  Deuterated nucleoside analogs of Formula (I) and the pharmaceutically acceptable salts thereof are provided by this disclosure The variables, e.g., B 1 , Y, R 1 , R 2 , R 3 , R 3 ′, R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 carry definitions set forth in the disclosure. Compounds of Formula (I) are deuterated at one or more positions and the deuterium enrichment at each deuterated positions is at least 50%. Compounds and salts of Formula (I) are useful for treating viral infections, including HCV infections.

  本公开提供了式（I）的氘代核苷类似物及其药用盐。变量，例如B1、Y、R1、R2、R3、R3'、R4、R5、R6、R7、R8和R9在本公开中有定义。式（I）的化合物在一个或多个位置上被氘代，且每个氘代位置的氘富集度至少为50%。式（I）的化合物和盐对治疗病毒感染，包括HCV感染，具有用处。
• 1',4'-THIO NUCLEOSIDES FOR THE TREATMENT OF HCV
  申请人：Idenix Pharmaceuticals, Inc.

  公开号：US20140364446A1

  公开（公告）日：2014-12-11

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 1′,4′-thio nucleoside compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula 3001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof; wherein Base, R A , R B , W, X, Y, and Z are as described herein.

  本文提供了用于治疗黄病毒科感染，包括HCV感染的化合物、组合物和方法。在某些实施例中，披露了核苷衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合给药。在某些实施例中，这些化合物是1′,4′-硫代核苷化合物，对于例如人体中的HCV感染具有显著的疗效和生物利用度。在某些实施例中，这些化合物的化学式如下： 或其药用可接受的盐、溶剂化合物、立体异构体、互变异构体或多形式；其中Base、R A 、R B 、W、X、Y和Z如本文所述。
• Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US20160257706A1

  公开（公告）日：2016-09-08

  A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

  一种结构的化合物： 或其药用可接受的盐或组合物，用于治疗感染或暴露于HCV病毒或其他在本文中更详细描述的疾病的宿主。
• [EN] BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION<br/>[FR] NUCLÉOTIDES DE PURINE BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUÉ-4'-FLUORO-N6-SUBSTITUÉ-6-AMINO-2-SUBSTITUÉ POUR LE TRAITEMENT DE L'INFECTION PAR LE VIRUS DE L'HÉPATITE C
  申请人：ATEA PHARMACEUTICALS INC

  公开号：WO2018013937A1

  公开（公告）日：2018-01-18

  Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX and Formula X that are highly active against the HCV virus when administered in an effective amount to a host in need thereof. The host can be a human or any animal that carries the viral infection. Methods of treating a subject suffering from a condition related to viral infections are also provided.

  当以有效剂量给予宿主时，化合物I、化合物II、化合物III、化合物IV、化合物V、化合物VI、化合物VII、化合物VIII、化合物IX和化合物X对HCV病毒具有高活性。宿主可以是患有病毒感染的人类或任何动物。还提供了治疗与病毒感染相关疾病的方法。
• [EN] 2'-DISUBSTITUTED SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES<br/>[FR] DÉRIVÉS NUCLÉOSIDES SUBSTITUÉS 2'-DISUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DE MALADIES VIRALES
  申请人：MERCK SHARP & DOHME

  公开号：WO2014059902A1

  公开（公告）日：2014-04-24

  2'-disubstituted substituted nucleoside derivatives of formula (I) and pharmaceutically acceptable salts thereof are disclosed:(1), wherein A is N3 or NH2 and X, Y, R1, R2, R3, R4,R5 and R18 are as defined herein. Compositions comprising at least one 2'-disubstituted nucleoside derivative, and methods of using the 2'-disubstituted nucleoside derivatives for treating or preventing HCV infection in a patient are disclosed.

  本文披露了公式(I)的2'-二取代核苷衍生物及其药学上可接受的盐：(1)，其中A为N3或NH2，X、Y、R1、R2、R3、R4、R5和R18如本文所定义。本文还披露了包含至少一种2'-二取代核苷衍生物的组合物，以及使用这些2'-二取代核苷衍生物治疗或预防患者HCV感染的方法。